Y 3
Alternative Names: Y-3Latest Information Update: 17 Jun 2024
At a glance
- Originator NeuroDawn
- Developer China Medical System; NeuroDawn
- Class Antidepressants; Small molecules; Vascular disorder therapies
- Mechanism of Action GABA A alpha 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
Most Recent Events
- 12 Jan 2024 NeuroDawn plans a phase III trial for Stroke in China (NeroDawn website, June 2024)
- 24 Dec 2023 Beijing Tiantan Hospital and NeuroDawn Pharmaceutical completes the phase II trial in Stroke in China (NCT06429384)
- 24 Aug 2023 Y 3 licensed to China Medical System in Macao, Hong Kong and China